ABUS

Form 8-KFalse000144702800014470282025-11-132025-11-13iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):  November 13, 2025

Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter)

British Columbia, Canada001-3494998-0597776 (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.) 701 Veterans Circle Warminster, Pennsylvania 18974 (Address of Principal Executive Offices) (Zip Code) (267) 469-0914 (Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Shares, without par valueABUSThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 13, 2025, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025 and certain other information. A copy of the press release is furnished herewith as Exhibit 99.1 hereto and is incorporated by reference herein

Item 8.01. Other Events.

On November 13, 2025, the Company posted an updated corporate presentation on its website at www.arbutusbio.com. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number Description

99.1 Press release dated November 13, 2025 99.2 Corporate Presentation dated November 13, 2025 104 Cover page interactive data file (formatted as inline XBRL).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arbutus Biopharma Corporation

Date: November 13, 2025By: /s/ Tuan Nguyen Tuan Nguyen Chief Financial Officer

Form 8-KFalse000144702800014470282025-08-042025-08-04iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):  August 4, 2025

Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter)

British Columbia, Canada001-3494998-0597776 (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.) 701 Veterans Circle Warminster, Pennsylvania 18974 (Address of Principal Executive Offices) (Zip Code) (267) 469-0914 (Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Shares, without par valueABUSThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 6, 2025, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025 and certain other information. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Director On August 4, 2025, Anuj Hasija notified the Company of his decision to resign from the Board of Directors of the Company (the “Board”) and all committees thereof, effective immediately. The resignation of Mr. Hasija is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Appointment of Director On August 4, 2025, the Board appointed Dr. Roger Sawhney to the Board, to serve until the Company’s 2026 annual general meeting of shareholders or until his successor is duly appointed and qualified, or until his earlier death, resignation or removal. Dr. Sawhney was also appointed as a member of the Board’s Audit Committee and Corporate Governance and Nominating Committee.

The Company expects to grant an initial option to acquire 157,600 common shares of the Company to Dr. Sawhney, and for the cash compensation for Dr. Sawhney to be consistent with the cash compensation generally provided to the Company’s non-employee directors. The option grant is expected to vest over a 3-year period with one-third vesting each year on the annual anniversary date of the grant, subject to Dr. Sawhney’s continued service on the Board. The option will be exercisable for 10 years from the date of the grant, at a price equal to the closing price of the Company’s common shares on the Nasdaq Stock Market on the date of the grant. The option grant will also be subject to the terms and conditions of the Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended, which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “SEC”) on May 28, 2024. Historical director compensation arrangements are described under “Director Compensation” in the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 4, 2025.

The Company also entered into an indemnity agreement with Dr. Sawhney in connection with his appointment to the Board. The indemnity agreement is in substantially the same form as the indemnity agreement for all other directors of the Company, which was filed as Exhibit 10.1 to the Company’s Annual Report on Form 10-K for the fiscal ye

Form 8-K0001447028 False 0001447028 2025-05-14 2025-05-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):  May 14, 2025

Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter)

British Columbia, Canada001-3494998-0597776 (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.) 701 Veterans Circle Warminster, Pennsylvania 18974 (Address of Principal Executive Offices) (Zip Code) (267) 469-0914 (Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Shares, without par valueABUSThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition. On May 14, 2025, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description

99.1 Press release dated May 14, 2025 104 Cover page interactive data file (formatted as inline XBRL).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arbutus Biopharma Corporation

Date: May 14, 2025By: /s/ Tuan Nguyen Tuan Nguyen Chief Financial Officer